[
    [
        {
            "time": "",
            "original_text": "【天风医药】贝达药业：前三季度净利润高增长，埃克替尼销量稳步增长",
            "features": {
                "keywords": [
                    "贝达药业",
                    "净利润",
                    "高增长",
                    "埃克替尼",
                    "销量"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药】贝达药业：前三季度净利润高增长，埃克替尼销量稳步增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)：控股股东凯铭投资质押396万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "控股股东",
                    "凯铭投资",
                    "质押"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：控股股东凯铭投资质押396万股",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "一图解码：加科思药业赴港IPO王印祥继贝达药业后的二次创业",
            "features": {
                "keywords": [
                    "加科思药业",
                    "IPO",
                    "王印祥",
                    "贝达药业",
                    "二次创业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "一图解码：加科思药业赴港IPO王印祥继贝达药业后的二次创业",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "人民金融·创新药指数涨0.9% | 智飞生物、贝达药业等公司的8个重磅药品有望在年底左右获批，18个报产创新药纳入优先审评",
            "features": {
                "keywords": [
                    "创新药指数",
                    "智飞生物",
                    "贝达药业",
                    "重磅药品",
                    "优先审评"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "人民金融·创新药指数涨0.9% | 智飞生物、贝达药业等公司的8个重磅药品有望在年底左右获批，18个报产创新药纳入优先审评",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：归母业绩高增长 埃克替尼保持良好增长态势",
            "features": {
                "keywords": [
                    "贝达药业",
                    "归母业绩",
                    "高增长",
                    "埃克替尼",
                    "增长态势"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：归母业绩高增长 埃克替尼保持良好增长态势",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：业绩表现亮眼 Q3埃克替尼销售出色 2020全年可期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩表现",
                    "Q3",
                    "埃克替尼",
                    "销售",
                    "2020全年"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：业绩表现亮眼 Q3埃克替尼销售出色 2020全年可期",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]